XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health.

We do this by acquiring the economic rights to potential milestone and royalty payments associated with pre-commercial clinical candidates and commercial therapies.  In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

There is so much promise in the biotech industry.  Once-fatal diseases now are manageable medical conditions thanks to scientific advances.  Many of us have been impacted by a new therapy that started in a biotech company. 

For investors, biotech represents the potential for big rewards, yet requires taking risks and investing significant capital.  We mitigate single-asset binary risk by taking a portfolio approach, building a portfolio of milestone and royalty rights to therapeutic assets that other companies are developing across multiple therapeutic indications and stages of clinical development. 

Over the course of our history, we had licensed antibody assets and technologies to pharmaceutical and biotech companies, building a sizeable portfolio of potential royalty and milestone payments.  Through our experience, we realized the royalty monetization market was largely focused on Phase 3 or commercial-stage products. 

When a biotech company seeks to raise money during the development process, they often are faced with three options – give up ownership of their company in order to raise equity capital, take on debt, or discontinue a promising program because financing isn’t available.  Historically, there have been few options to monetize royalties at a pre-commercial stage. 

We knew we had an opportunity to build upon XOMA Royalty’s strong license portfolio and deliver shareholder value by addressing a clear market need.  We offer a fourth option to the biotech industry – access to non-dilutive, non-recourse capital in exchange for the contractual rights to future milestones and royalties.